Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)
Launched by GRACE LIM, MD, MS · Jun 7, 2023
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
Pain management for women having a cesarean delivery is rather limited and risks poor pain control, depressed mood, and poor recovery following the cesarean delivery. Current cesarean pain management treatments ignore the multidimensionality of pain, including the influence of mood on pain. Recent evidence suggests that ketamine may provide successful post-surgical pain management, opioid reduction, and rapid reduction of depressive symptoms. The current study aims to identify an appropriate dose of ketamine for post-cesarean pain management while minimizing potential dose-dependent side ef...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Adults 18 years and older
- • Cesarean Delivery
- • American Society of Anesthesiologists Physical Status of 2 or 3
- • Neuraxial anesthesia with neuraxial morphine
- • Term delivery ≥37 weeks gestation
- • Either planning not to breastfeed, OR receiving ketamine as part of routine clinical care
- Exclusion Criteria:
- • General anesthesia
- • Allergy to study medications
- • ASA PS 4 or higher
- • Contraindications to neuraxial anesthesia
- • Preterm delivery (\<37 weeks gestation)
- • Anticipated fetal-neonatal complex care plan
- • Participating in another pain intervention trial
- • Hypertensive disorder of pregnancy
- • Pre-eclampsia with severe features
- • Hemodynamic instability
- • Medical History exclusions: ketamine or PCP (phencyclidine) abuse, schizophrenia or psychosis, liver or renal insufficiency, uncontrolled hypertension, chest pain, arrhythmia, head trauma, or intracranial hypertension, uncontrolled thyroid disease, or other contraindications to ketamine
About Grace Lim, Md, Ms
Dr. Grace Lim, MD, MS, is a distinguished clinical trial sponsor with extensive expertise in medical research and patient care. With a strong academic background and a commitment to advancing healthcare, Dr. Lim specializes in innovative therapeutic approaches and evidence-based practices. Her leadership in clinical trials reflects a dedication to improving patient outcomes and contributing to the scientific community. Dr. Lim's collaborative approach fosters partnerships with healthcare professionals and research organizations, ensuring the successful execution of trials that adhere to the highest ethical standards and regulatory guidelines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Grace Lim, MD, MSc
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported